Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New IDegLira Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change, and Lower Rate of Hypoglycaemia Versus Insulin Glargine

BOSTON, June 7, 2015 /PRNewswire/ — – 166-OR For medical and consumer media in the US only  New phase 3b findings showed adults with type 2 diabetes treated with IDegLira, the investigational once-daily, single-injection combination of insulin degludec and liraglutide in the United States, demonstrated statistically significant reduction in HbA1c (average blood glucose over the […]

Read More »

50 Years of Diabetes Research and Treatment

BOSTON, June 6, 2015 /PRNewswire-USNewswire/ — From how people test their glucose levels to how long they can expect to live, almost everything has changed over the past 50 years for Americans with diabetes. A special symposium held at the American Diabetes Association’s 75th Scientific Sessions features a look back at what physicians and researchers […]

Read More »

Lilly’s Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes

INDIANAPOLIS, June 6, 2015 /PRNewswire/ — Eli Lilly and Company’s (NYSE: LLY) basal insulin peglispro (BIL) consistently demonstrated superior hemoglobin A1c (HbA1c) reduction in people with type 2 diabetes compared to insulin glargine across three Phase III trials. The results were presented today at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston.1,2,3 The trials […]

Read More »

Sanofi’s Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin

PARIS, June 6, 2015 /PRNewswire-USNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide) met all co-primary endpoints in a clinical trial (GetGoal Duo-2) comparing its use as a once-daily add-on to basal insulin versus the addition of rapid acting insulin injected once each day at main meal (basal-plus) or three times daily […]

Read More »

Eli Lilly Commits 780,000 Additional Vials Of Insulin To Life For A Child

INDIANAPOLIS, June 4, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) has committed another 780,000 vials of insulin to the International Diabetes Federation’s Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International […]

Read More »

Global Drug Delivery Infusion And Injection Technologies Market Forecast To Exceed $17.6 Billion By 2020

HUNTINGTON BEACH, Calif., June 4, 2015 /PRNewswire/ — A new analysis by Life Science Intelligence (LSI), Global Markets for Drug Delivery: Infusion and Injection Technologies in 2015, has concluded that despite efforts to push back on the cost of acquiring new medical devices, innovative drug delivery technologies with higher prices should see greater adoption in […]

Read More »

Childhood trauma may raise risk of type 1 diabetes

Traumatic events during childhood may increase kids’ risk of developing type 1 diabetes, a Swedish study suggests. The researchers questioned more than 10,000 families and found that children who experienced an extremely stressful life event – like divorce, illness or death in the family – were about three times more likely to develop type 1 […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom